The performance of the Myo1g methylation biomarker in differentiating the HCC cases from controls was also better than that of the AFP AUC: 0.818 (0.769–0.867) vs. 0.796 (0.744–0.847), with a sensitivity of 78.8%, specificity of 84.8%, PPV of 85%, NPV of 78.5%, and Kappa of 0.633. Here, AFP is linked to hepatocellular carcinoma.